Establishment Labs Holdings Inc.
CRFinancials
Valuation Metrics
Establishment Labs Holdings Inc.'s Market Cap is $2.05B. At end of 2025 it was $2.16B. Ranked #2016 of 3,121 in US market (top 65%), #768 of 1,463 on NASDAQ (top 52%), #122 of 205 in Health Care Equipment & Services (top 60%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.05B | US#2,016/3,121 Sec#122/205 |
| Revenue | $246M | US#2,531/3,121 Sec#165/205 |
| Net Income | $-39M | US—/3,121 Sec—/205 |
| Total Assets | $352M | US#2,883/3,121 Sec#170/205 |
| Net Assets | $22M | US#2,897/3,121 Sec#188/205 |
| Employees | 1,004 | US#1,987/3,121 Sec#133/205 |
| Value | ||
| P/B | 94.75x | US#2,908/3,121 Sec#192/205 |
| P/S | 8.33x | US#2,620/3,121 Sec#175/205 |
| FCF Yield | -2.05% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -179.99% | US#2,839/3,121 Sec#188/205 |
| ROA | -11.05% | US#2,683/3,121 Sec#158/205 |
| Op. Margin | -7.63% | US#2,524/3,121 Sec#151/205 |
| Revenue Growth | 38.55% | US#322/3,121 Sec#19/205 |
| Financial Health | ||
| Debt Ratio | 1528.76% | US#2,818/3,121 Sec#190/205 |
| Total Debt | $264M | US#2,157/3,121 Sec#116/205 |
| FCF | $-42M | US#2,506/3,121 Sec#175/205 |
| Cash | $71M | US#2,419/3,121 Sec#149/205 |
| Current Ratio | 3.84x | US#600/3,121 Sec#60/205 |
| Performance | ||
| 1Y Return | 77.90% | US#314/3,121 Sec#32/205 |
| 1M Return | -7.52% | US#2,133/3,121 Sec#155/205 |
| From 52W High | -28.72% | US#1,998/3,121 Sec#138/205 |
| 1Y MDD | -31.35% | US#1,517/3,121 Sec#71/205 |
| Trading | ||
| Volume | 269,136 shares | US#2,480/3,121 Sec#175/205 |
| Trading Value | $19M | US#1,905/3,121 Sec#129/205 |
| Per Share | ||
| EPS | $-1.32 | US—/3,121 Sec—/205 |
| BPS | $0.73 | US#2,730/3,121 Sec#184/205 |
Company Info
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.